Essex Property Trust, Inc. vs Johnson & Johnson — how do they compare? Essex Property Trust, Inc. trades at $280.53 (market cap $18.15B), while Johnson & Johnson trades at $260.02 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 34.5× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| ESS | JNJ | |
|---|---|---|
Market Cap | $18.15B | $626.09B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $267.24 |
52-Week Low | $239.61 | $172.78 |
Enterprise Value | $24.75B | $654.37B |
Dividend Yield | 3.93% | 2.06% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
ESS trades at $282.11, down 0.39% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 EPS of $0.97, missing expectations, but raised full-year guidance after strong property NOI growth. Revenue reached $1.89B in 2025 with a net income margin of 35.48%, though profitability is trending lower in 2026. Recent news includes ESS being named a top GreenTech company and signing a 500 MWh energy storage agreement with Juniper Energy.
The outlook is mixed: raised guidance and institutional buying support upside, but technical weakness and earnings miss pose near-term risks. Valuation ratios like P/E of 19.9 and P/S of 9.05 are reasonable for a REIT, yet debt levels and regional market volatility require caution. Analyst consensus is a Moderate Buy with a $305.86 price target, suggesting 8.4% potential upside from current levels.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Trailing returns across standard periods
Latest headlines on both assets
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →